SRZN (SRZN) Stock Analysis
Verdict: AVOID
Surrozen offers high-risk clinical Wnt-pathway pipeline exposure, but a 108% unbacked price spike exposes buyers to severe downside.
Investment score: 37/100
Is SRZN Stock Worth Reviewing? AI Model Thesis
The model views Surrozen as an AVOID at $33.68 USD following an unbacked 108.4% single-day rally. Fundamental balance sheet deficits and extreme earnings volatility offset clinical pipeline potential.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| FHTX | -3.64 | -3.14 | 5.75 | -2.98 | — | -1.76 |
| WHWK | -3.45 | 1.75 | 0.00 | -1.66 | — | 0.00 |
| CMPX | -2.73 | 1.28 | 0.00 | -2.46 | — | 0.00 |
| NKTX | -1.82 | 0.86 | 0.00 | -2.34 | — | 0.00 |
| TARA | -2.46 | 1.27 | 0.00 | -2.50 | — | 0.00 |
Should You Buy or Sell SRZN Stock? Model Reasoning
The model identifies significant risk in buying SRZN following a 108.4% single-day technical surge to $33.68 USD without fundamental news catalysts. While $89.25M in cash supports ~35 months of clinical development runway, negative book equity (-$187.8M USD), recurrent EPS misses (-$14.03 vs -$1.21 est in Q4 2025), and insider selling at $21.25 USD make the current price level vulnerable to sharp pullbacks.
SRZN Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Annual operating cash burn remains between $30M and $40M, maintaining cash runway of ~35 months from 2025 cash balance ($89.25M)","No commercial product launches before 2029, with analyst EPS estimates remaining negative (-$3.61 in 2027 to -$3.89 in 2029)","Peer group multiples (EV/EBITDA of -0.47x vs peer average -2.4x) remain constrained by sector-wide pre-revenue clinical risks"]
SRZN Risk & Opportunity Analysis
Key Investment Risks
- Extreme retracement risk post-squeeze — A rapid unwinding of speculative momentum could push the stock back to its pre-breakout support of $16.16 USD, implying a 52.0% loss from $33.68 USD.
- Institutional insider distribution — TCG Crossover GP II sold 325,000 shares at $21.25 USD on July 22, 2026, indicating institutional willingness to lock in liquidity well below current market prices.
- Chronic operational losses and negative book equity — SRZN missed quarterly EPS estimates significantly, including -$14.03 vs -$1.21 est on December 31, 2025, driving retained earnings to -$527.29M USD.
- Binary clinical trial trial risk without commercial backstop — Forward revenue estimates remain at $0.00B USD through 2029; any clinical hold or adverse trial result would severely impair valuation before December 31, 2028.
Growth Opportunities & Upside Drivers
- Boehringer Ingelheim strategic partnership validation — Collaborative research agreements provide external validation for Wnt antibody platforms and potential developmental milestone payments exceeding $100M USD through 2028.
- Multi-year cash runway buffer — Cash reserves of $89.25M USD as of December 31, 2025 provide approximately 35 months of operating runway at the $30.37M USD annual FCF burn rate, supporting operations into Q4 2028.
- Targeting large ophthalmic markets — Lead candidates SZN-814 and SZN-413 target diabetic macular edema and wet AMD, addressing a combined global addressable market projected to exceed $15B USD by 2030.
- Clean debt structure — Total debt of $6.64M USD as of December 31, 2025 is modest relative to $91.56M USD in current assets, limiting credit interest pressure.
SRZN Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About SRZN (SRZN)
Is SRZN stock a good investment?
The cached TradeMates AI model rates SRZN as AVOID with an investment score of 37/100. The model views Surrozen as an AVOID at $33.68 USD following an unbacked 108.4% single-day rally. Fundamental balance sheet deficits and extreme earnings volatility offset clinical pipeline potential. This is algorithmic model output, not personal investment advice.
Does SRZN pay a dividend?
The cached stock data on this page does not show a positive dividend yield for SRZN. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does SRZN stock do?
Clinical-stage biotechnology model focused on discovering and developing Wnt pathway modulating antibodies for tissue repair, deriving revenue from research collaborations and licensing milestones (e.g., Boehringer Ingelheim, TCGFB) rather than commercial product sales.
What is SRZN stock's price target?
This cached page does not contain a precise model fair value for SRZN.
Is SRZN stock a buy?
The TradeMates model verdict for SRZN is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.
Is SRZN a good dividend stock?
SRZN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.